UNITAID approves grants of over $140 million
Friday, December 13, 2013
UNITAID’s Executive Board has approved over $140 million in new funding. The organisation remains committed to children living with HIV/AIDS and will continue funding treatment for almost 100,000 children in Malawi, Mozambique and Uganda. Additional investments have been targeted to further stabilize the paediatric HIV treatment market. UNITAID will also continue funding for existing projects to shape markets for HIV/AIDS, malaria and tuberculosis.
Funding of $30 million is provided for Malawi, Mozambique and Uganda for paediatric HIV treatment until 2015 and $12.6 million has been allocated to ensure better coordination for the paediatric HIV medicines market.
“More investment in paediatric HIV treatment is still needed, despite our huge success in creating incentives for companies to develop treatment for children living with HIV in low-income countries,” said Dr Philippe Douste-Blazy, Chairman of the UNITAID Executive Board. “Until the day when no child is born with HIV, UNITAID will remain committed to the right of children living with the virus to lead healthy, normal lives.”